The Report
Verified funding, headquarters, and leadership news from the world's most innovative businesses
189 reports and counting
Varda Raises $251M Series D for Space-Based Pharmaceutical Processing
Varda Space Industries raised a $251 million Series D led by Lux Capital and Natural Capital to scale space-based pharmaceutical processing.
SpyGlass Pharma Opens New Headquarters in Irvine
SpyGlass Pharma opened a 33,000-square-foot headquarters in Irvine, California, on August 27, 2026, moving from its former facility in Aliso Viejo as it prepares for its first product launch.
The Emmes Group Appoints Rama Kondru Chief Executive Officer
The Emmes Group’s Board appointed Rama Kondru, most recently CEO of its Veridix AI, technology, and data sciences business, as Chief Executive Officer.
Collegium Pharmaceutical Plans Headquarters Move to Downtown Boston
Collegium Pharmaceutical plans to move its corporate headquarters from Stoughton to One Lincoln in downtown Boston during the first quarter of 2027.
Apnimed Appoints Kevin R. Lind Chief Executive Officer
Apnimed appointed Board Chair Kevin R. Lind as CEO, succeeding founder Lawrence G. Miller, who will become Vice Chair, as the company builds capabilities toward a potential commercialization of AD109.
Vertex Pharmaceuticals raises $120B Public at $130B valuation
Vertex Pharmaceuticals raises $120B in Public at $130B valuation. Pharmaceutical company...
Takeda Pharmaceutical raises $60B Public at $65B valuation
Takeda Pharmaceutical raises $60B in Public at $65B valuation. Pharmaceutical company...
Takeda Pharmaceutical Raises $60B in Public
Takeda Pharmaceutical, a Pharmaceuticals company based in 1-1 Doshomachi 4-chome, Osaka 540-8645, Japan, has raised $60B in Public at a $65B valuation led by Public.
Teva Pharmaceutical Raises $10B in Public
Teva Pharmaceutical, a Pharmaceuticals company based in 124 Dvora HaNevi'a Street, Tel Aviv 6944020, Israel, has raised $10B in Public at a $12B valuation led by Public.
Showing 9 reports • Page 1 • Category: all
Stay ahead of the market
Get weekly insights delivered to your inbox. No spam, just intelligence.